Biocon BIOCON
India's largest biosimilars company (Biocon Biologics, now 100% owned) plus generics/APIs and a majority stake in Syngene
Mapped in 1 theme: Pharmaceuticals.
Where Biocon sits in the supply chain
Biocon appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Biosimilars, vaccines & biologics
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 14,756 | 15,262 | 16,927 |
| Net profit | 1,298 | 1,429 | 369 |
Latest-year revenue ₹16,927 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Broad commercial biosimilar portfolio (insulins, trastuzumab, bevacizumab, adalimumab, aflibercept, ustekinumab, denosumab)
- Full ownership of Biocon Biologics completed in 2026 (Viatris, Serum and minority stakes swapped in)
- Majority shareholder of Syngene (CRO/CDMO)
Risks
- High leverage from the Viatris biosimilars deal - FY26 profit just ₹369 Cr, ROE near zero
- Biosimilar price erosion as more competitors launch
- Past USFDA issues at Bengaluru and Malaysia sites
Common questions
What does Biocon do?
India's largest biosimilars company (Biocon Biologics, now 100% owned) plus generics/APIs and a majority stake in Syngene.
Where does Biocon sit in the supply chain?
Biocon (NSE: BIOCON) is mapped in 1 supply-chain layer: Biosimilars, vaccines & biologics (Pharmaceuticals).
Who are Biocon's peers?
In the Biosimilars, vaccines & biologics layer of Pharmaceuticals: Serum Institute of India (not NSE-listed), Bharat Biotech (not NSE-listed), Biological E (not NSE-listed), Panacea Biotec, Intas Pharmaceuticals (not NSE-listed), Dr Reddy's Laboratories and 1 more.
What is Biocon's market cap and valuation?
As of 30 Oct 2026: market cap ₹57,316 Cr, P/E 78.8x, ROCE 3.6%, ROE 1.4%, dividend yield 0.14%.